Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | PAK1 | Q13153 | 3/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMO | Q99835 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17698998 | 0.84 | ALDH1A1 (0.53) | MEN1KMT2APKMTSHRHTT | |
| SCHEMBL3779464 | 0.82 | CKS1B (0.53) | MEN1KMT2AGFERPKMTSHR | |
| SCHEMBL16162195 | 0.81 | MEN1 (0.51) | MEN1KMT2AGFERPKMTSHR | |
| Hydrochloric Acid SCHEMBL1268228 | 0.80 | KMT2A (0.59) | MEN1KMT2AGFERPKMTSHR | |
| SCHEMBL16269253 | 0.79 | HTR1A (0.44) | MEN1KMT2AGFERPKMTSHR | |
| SCHEMBL9310951 | 0.79 | KMT2A (0.66) | MEN1KMT2AGFERPKMTSHR | |
| SCHEMBL3205743 | 0.79 | KMT2A (0.46) | MEN1KMT2APAK1DRD4 | |
| SCHEMBL15662150 | 0.78 | MEN1 (0.47) | MEN1KMT2AGFERPKMTSHR | |
| SCHEMBL16269780 | 0.77 | MEN1 (0.52) | MEN1KMT2AGFERPKMTSHR | |
| SCHEMBL1267034 | 0.77 | MEN1 (0.52) | MEN1KMT2AGFERPKMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9579319-B2 | Heterocyclic compounds as hedgehog signaling pathway inhibitors | REDX PHARMA PLC (GB) | 2017-02-28 | — | — | US | disclosed |
| US-20160113928-A1 | HETEROCYCLIC COMPOUNDS AS HEDGEHOG SIGNALING PATHWAY INHIBITORS | REDX PHARMA PLC (GB) | 2016-04-28 | — | — | US | disclosed |
| US-9000023-B2 | Disubstituted phthalazine hedgehog pathway antagonists | ELI LILLY AND COMPANY (US) | 2015-04-07 | — | — | US | disclosed |
| WO-2014191736-A1 | HETEROCYCLIC COMPOUNDS AS HEDGEHOG SIGNALING PATHWAY INHIBITORS | REDX PHARMA LIMITED (GB) | 2014-12-04 | — | — | WO | disclosed |
| EP-2356108-B1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-10-15 | — | — | EP | disclosed |
| EP-2443104-B1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | LILLY CO ELI (US) | 2013-04-17 | — | — | EP | disclosed |
| US-20120316174-A1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2012-12-13 | — | — | US | disclosed |
| US-8273742-B2 | Disubstituted phthalazine hedgehog pathway antagonists | ELI LILLY AND COMPANY (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2443104-A1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | Eli Lilly and Company (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-2356108-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-08-17 | — | — | EP | disclosed |
| US-20100324048-A1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-12-23 | — | — | US | disclosed |
| WO-2010147917-A1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010055267-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324048-A1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | SHH, GLI1, SMO | MEN1 2224/4885KMT2A 590/4885GFER 4314/4885 |
| US-20160113928-A1 | HETEROCYCLIC COMPOUNDS AS HEDGEHOG SIGNALING PATHWAY INHIBITORS | SMO, SHH, GLI1 | MEN1 467/4885KMT2A 708/4885GFER 2624/4885 |
| US-20120316174-A1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | SHH, GLI1, SMO | MEN1 2224/4885KMT2A 590/4885GFER 4314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.